 SAN DIEGO and TORONTO, April 25, 2022 GLOBE NEWSWIRE -- Aptose Biosciences Inc. Nasdaq: APTO; TSX: APS, a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended March 31, 2022, on Monday, May 9, 2022 after the close of the market, and provide a corporate update. 